Identification of Site-specific Genome Alterations in Advanced Colorectal Cancer (SCRUM-Japan GI-screen 2013-01-CRC substudy 003)
- Conditions
- Advanced colorectal cancer
- Registration Number
- JPRN-UMIN000031242
- Lead Sponsor
- St. Marianna University School of Medicine
- Brief Summary
Patients with right-sided tumors had worse survival,left-sided tumors with wt RAS had favorable outcomes when treated with anti-EGFR antibodies and cecum tumors had a poor prognosis when treated with bevacizumab. The rate of gene alterations varied depending on the primary site. In addition, gene alterations of KRAS, BRAF, SMAD4, or TP53 had different contributions to survival from site to site. KRAS, BRAF, PTEN, or SMAD4 mutations were associated with the efficacy of bevacizumab or anti-EGFR mAb.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 569
Not provided
1)Patients whose specimens were collected from metastatic site or unknown. 2)Patients who have administerd chemotherapy, including anti-EGFR therapies or anti-angiogenetic agents for metastatic disease before collecting the specimens. 3)Judged by the investigator to be inappropriate for study participation for any reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method